The ITSN2 Knockout HT29 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, with targeted disruption of the ITSN2 gene. This loss-of-function model provides researchers with a robust tool to investigate the role of the ITSN2 scaffold protein in clathrin-mediated endocytosis and associated signaling networks. The polyclonal knockout format retains natural genetic heterogeneity while eliminating functional ITSN2 expression, enabling comparative studies without the biases of monoclonal selection. This population-based approach is well-suited for functional assays requiring physiological variability and is an ideal starting point for downstream applications such as clonal isolation if desired.
HT29 cells are a widely used intestinal epithelial model established from a primary colorectal adenocarcinoma in a 44-year-old female. These adherent cells display an epithelial morphology, are capable of mucin secretion, and harbor a TP53 mutation while remaining KRAS wild-type. Under appropriate culture conditions, HT29 cells can undergo enterocytic differentiation, making them valuable for studying colorectal cancer biology, epithelial barrier function, and drug absorption. Their well-characterized signaling pathways, including active EGFR and MAPK cascades, provide a relevant genetic and molecular context for interrogating genes implicated in tumor progression, metastasis, and therapeutic resistance. This host cell background is particularly advantageous for examining endocytic trafficking and its impact on oncogenic signaling.
ITSN2 encodes a multidomain scaffold protein that integrates clathrin-mediated endocytosis with actin cytoskeleton remodeling. Activated by upstream signals such as EGFR activation, SRC kinase, and phosphatidylinositol 4,5-bisphosphate, ITSN2 interacts with key partners including Epsin, Eps15, dynamin, N-WASP, cdc42, synaptojanin, Src, and Grb2. Through these interactions, ITSN2 facilitates the internalization of receptor tyrosine kinases by coupling the endocytic machinery to actin polymerization via N-WASP and cdc42. It functions downstream of receptor activation to coordinate clathrin-coated pit dynamics and subsequent receptor trafficking, thereby modulating signal transduction through the MAPK pathway. By scaffolding the endocytic and actin regulatory modules, ITSN2 controls the spatiotemporal strength and duration of signaling outputs, influencing cellular processes such as migration, proliferation, and differentiation.
In the context of HT29 colorectal adenocarcinoma cells, loss of ITSN2 disrupts the coordinated coupling between endocytosis and actin remodeling, offering a powerful model to dissect how aberrant receptor trafficking contributes to colorectal cancer progression. The TP53-mutant background and constitutive EGFR signaling in HT29 cells make this knockout particularly suited to explore ITSN2-dependent modulation of EGFR internalization and its downstream consequences on MAPK pathway activation. This model enables researchers to uncouple ITSN2??s scaffold function from other endocytic adaptors, shedding light on its specific role in metastatic behavior, invasion, and potential resistance to EGFR-targeted therapies. By studying the impact of ITSN2 ablation on actin dynamics and receptor recycling, investigators can gain mechanistic insights into the molecular drivers of tumor aggressiveness.
This polyclonal knockout cell population is a versatile tool for a wide range of functional assays. Researchers can employ western blotting to confirm loss of ITSN2 protein, RT-qPCR to quantify transcript levels, and immunofluorescence to examine subcellular localization changes of endocytic or actin-associated proteins. Functional studies such as transferrin uptake assays allow precise measurement of clathrin-mediated endocytosis rates, while scratch wound healing and transwell invasion assays evaluate effects on cell migration and invasion. MTT and proliferation assays provide insight into growth alterations, and phospho-EGFR signaling analysis by flow cytometry or western blot can delineate changes in receptor activation. These applications establish the ITSN2 Knockout HT29 Polyclonal Cells as a valuable resource for investigating endocytic mechanisms in cancer, receptor trafficking, and colorectal adenocarcinoma biology. For further details or inquiries, please contact Ascent Research.
